Corporate news

2014-01-31 17:35:00
Resolutions of the Sole Shareholder
EXTRAORDINARY INFORMATION on the resolutions of the Sole Shareholder
2013-12-18 21:35:00
Change in the Board of Directors
The revocation of Dr. Jean-Philippe Seta from the Board of Directors
2013-12-02 17:35:00
Strategic agreement and plant inauguration
Strategic partnership agreement signed with the Hungarian government and a new API Research and Development Centre inaugurated.
2013-11-15 09:49:00
Shareholder notification
Influence of Sertorius Global Opportunities Fund eliminated
2013-11-14 17:35:00
Announcement on the financial settlement of the offer of the Servier Group
Announcement received by Egis Pharmaceuticals PLC on the financial settlement of the offer of the Servier Group
2013-11-14 09:46:00
On the declaration of the Servier Group to exercise call option right
On the declaration of the Servier Group to exercise call option right together with the relevent documentation.
2013-11-07 17:35:00
The result of the Offer of the Servier Group
Extraordinary Information on the result of the voluntary public purchase offer of the Servier Group.
2013-10-31 17:35:00
Shareholder notification of reaching 5% share holding
Shareholder notification: influence of Sertorius Global Opportunities Fund exceeding 5%.
2013-10-01 10:12:00
Opinion of the Board of Directors regarding the offer of Servier Group
The opinion of the Board of Directors regarding the voluntary public purchase offer of Servier Group.
2013-09-27 09:59:00
Approval of Servier's voluntary public purchase offer by HFSA
Approval of Servier's voluntary public purchase offer by HFSA. The commencement date of the acceptance period, during which the Offer can be accepted, is October 2, 2013 and the closing date is November 5, 2013.
2013-09-24 11:00:00
Voluntary public purchase offer
Voluntary public purchase offer in the attached document.
2013-09-13 10:57:00
Marketing authorisation for biosimilar infliximab in EU
Egis is first to launch biosimilar monoclonal antibody within the European Union.
2013-04-23 12:48:00
Announcement on dividend payment in 2013
Announcement on dividend payment in 2013 Record date: May 14, payment initiated on May 22.
2013-03-25 12:45:00
Resolving outstanding patent litigation
Egis and its business partner Actavis (formerly Watson), have reached a settlement agreement with AstraZeneca related to the generic version of Crestor® tablets (rosuvastatin calcium)as well as rosuvastatin zinc alternate salt product developed by Egis.
2012-05-24 14:15:00
Extraordinary information
In accordance with Section 61 of Act CXX of 2001 on Capital Markets („Capital Market Act”) on basis of shareholder notification Egis Pharmaceuticals PLC announces that the influence of Tradewinds Global Investors, LLC (2049 Century Park East, 20th Floor, Los Angeles, California 90067, USA) in the Company dropped below 5%, now holding 381,323 Egis shares that represent 4.898% of total votes.
2012-04-06 14:18:00
Details of divident payment - 2012
Record date: April 23, beginning of dividend payment: May 2
2012-03-30 14:37:00
Tradewinds reduced shareholding in Egis below 10%
According to shareholder notification the holding of Tradewinds Global Investors, LLC is reduced below 10%.
2012-03-26 14:34:00
Involvement in US patent challenge
EXTRAORDINARY INFORMATION - Egis confirms involvement in US patent challenge.
2012-02-01 14:33:00
Change in phone numbers
Change in the primary phone numbers at the main headquarters of the Company.
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox